Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of intravenous human immunoglobulin 10% for primary immune thrombocytopenia in adults and adolescents
CTR20242489Phase 3Completed
- Sponsor
- Pacific Shuanglin Bio-pharmacy
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune serum globulin in immune thrombocytopenia (ITP), sponsored by Pacific Shuanglin Bio-pharmacy. Primary endpoint: Platelet response rate by day 7. Started Aug 2024; status: completed.
02
Drugs
immune serum globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20242489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242489.